Syndax Pharmaceuticals (STU:1T3) Additional Paid-In Capital : €1,406.49 Mil(As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Additional Paid-In Capital?

Syndax Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2024 (€1,345.23 Mil) to Dec. 2024 (€1,441.20 Mil) but then stayed the same from Dec. 2024 (€1,441.20 Mil) to Mar. 2025 (€1,406.49 Mil).

Syndax Pharmaceuticals's annual additional paid-in capital increased from Dec. 2022 (€1,096.26 Mil) to Dec. 2023 (€1,335.49 Mil) and increased from Dec. 2023 (€1,335.49 Mil) to Dec. 2024 (€1,441.20 Mil).

Syndax Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Syndax Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Additional Paid-In Capital Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

674.71

842.54

1,096.26

1,335.49

1,441.20

Syndax Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,350.04	1,373.07	1,345.23	1,441.20	1,406.49

Syndax Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Syndax Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SNDX:USA 1T3:Germany

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines